Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Navitoclax - AbbVie

Next Previous
X
Search
Drug Profile

Navitoclax - AbbVie

Alternative Names: ABT-263; RG 7423; RG 7433

Latest Information Update: 30 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Abbott Laboratories
  • Developer Abbott Laboratories; AbbVie; Genentech
  • Class Antifibrotics; Antineoplastics; Benzamides; Morpholines; Piperazines; Senotherapeutics; Small molecules; Sulfones
  • Mechanism of Action Apoptosis stimulants; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Myelofibrosis
  • Phase I/II Myelodysplastic syndromes; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours
  • Phase I Haematological malignancies; Ovarian cancer; Triple negative breast cancer
  • Discontinued Chronic lymphocytic leukaemia; Crohn's disease; Head and neck cancer; Idiopathic pulmonary fibrosis; Lymphoid leukaemia; Lymphoma; Non-small cell lung cancer; Small cell lung cancer; Vascular disorders

Most Recent Events

  • 30 Aug 2024 Pharmacodynamics data from preclinical studies in Vascular disorders presented at the Annual Congress of the European Society of Cardiology (ESC Congress 2024)
  • 29 Aug 2024 Discontinued - Phase-I for Precursor cell lymphoblastic leukaemia-lymphoma (Combination therapy, In adolescents, In children, Second-line therapy or greater, In adults) in Australia (PO)
  • 29 Aug 2024 Discontinued - Preclinical for Head and neck cancer (Combination therapy) in USA (PO)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top